[1]
Shakeri, A. and Adanty, C. 2020. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review. Journal of Population Therapeutics and Clinical Pharmacology. 27, 1 (Jan. 2020), e25-e31. DOI:https://doi.org/10.15586/jptcp.v27i1.655.